Pfizer and BioNTech have begun testing a vaccine against the Omicron strain

This was stated in the corporate letter.

The study will include people between the ages of 18 and 55. The 1,420 participants will be divided into three groups, where they will study the various applications of the current Pfizer/BioNTech vaccine against COVID-19 and the Omicron strain-based vaccine.

Thus, the first group will include participants who have already received two doses of Pfizer/BioNTech against COVID-19 90-180 days ago. As part of the study, they will receive one or two doses of the new vaccine.

The second group will include those who have already received three doses of Pfizer/BioNTech and will be offered one dose of Omicron.

The third group includes those who have not yet been vaccinated against the coronavirus. They will receive three doses of the vaccine against a new strain of coronavirus.

«Vaccines continue to provide reliable protection against the acute course of disease caused by Omicron. However, the new data indicates that protection from infection and from mild to moderate disease declines faster than in previous breeds.Said Ugur Sahin, CEO and Co-founder of BioNTech.

Pfizer CEO Albert Burla announced that a vaccine against the Omicron coronavirus strain will be ready in March 2022. This vaccine is expected to target other strains.

According to Burley, it is not clear if the “Omicron vaccine” will be needed and how it will be used. But Pfizer is said to have the doses ready, as some countries want the drug to be ready as quickly as possible.

What is known about the new breed?

The strain, currently called B.1.1.529, or Omicron, was first discovered in Botswana, then in South Africa and Hong Kong in a South African traveler.

The researchers said the new strain had 32 mutations in the viral spike protein, which the virus transmits to cells and multiplies. The new strain is believed to be more contagious than the previous strain.

Some vaccines work by delivering a gene into cells with a protein encoded in a spike shape, the cell produces this protein, and the human body produces an immune response. Therefore, scientists are concerned that the new mutations may impair the effectiveness of vaccines against COVID-19. It appears that booster vaccinations may be the key to protecting against infection.

The new strain has been registered in at least 106 countries. The World Health Organization predicted that in the near future “Omicron” will be the most popular option in the world.

Bitcoin Trader

Bitcoin Trader

Leave a Reply

Your email address will not be published. Required fields are marked *